Advertisement
Screener

ImmuCell Corporation (ICCC) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

2.8 / 5 stars · 68/120 Roast Me

ImmuCell Corporation Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

ImmuCell Corporation (ICCC) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of $513.29 thousand for the 3-month period ending 2022-03-31, per its 10-Q/A filed 2022-11-21.

Discontinued › Income Statement › Net Income

us-gaap:ProfitLoss · last filed 2022-11-21

  • ImmuCell Corporation net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2022-03-31 was $513.29K.
  • ImmuCell Corporation net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2021-03-31 was -$441.30K.
Period endNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed
2022-03-31$513.29K
10-Q/A · filed 2022-11-21
$735.67K
10-Q · filed 2022-05-12
2021-03-31-$441.30K
10-Q/A · filed 2022-11-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
VOLITIONRX LTD (VNRX)$0.003B-0.64
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92